SCHEDULE: State Street Discloses Stake in Protagonist Therapeutics

State Street Corporation has reported beneficial ownership of 4.9% of Protagonist Therapeutics Inc.'s common stock as of March 31, 2026.

Summary

• State Street Corporation has filed a Schedule 13G, indicating its beneficial ownership of Protagonist Therapeutics Inc. common stock.
• As of March 31, 2026, State Street Corporation beneficially owns 3,116,804 shares, representing 4.9% of the class of securities.
• The filing specifies that State Street Corporation has shared power to vote or direct the vote for 2,956,605 shares and shared power to dispose or direct the disposition of 3,116,804 shares.
• State Street Corporation is identified as a "HC" (likely meaning Holding Company or similar institutional classification) and is filing under Rule 13d-1(b).
• Several subsidiaries of State Street Corporation are listed, including SSGA FUNDS MANAGEMENT, INC., STATE STREET BANK AND TRUST COMPANY, STATE STREET GLOBAL ADVISORS EUROPE LIMITED, STATE STREET GLOBAL ADVISORS LIMITED, STATE STREET GLOBAL ADVISORS TRUST COMPANY, and STATE STREET GLOBAL ADVISORS, LTD.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It is a routine disclosure of institutional ownership and does not provide new operational or financial information about Protagonist Therapeutics Inc. itself.

Positives

• State Street Corporation's investment indicates confidence in Protagonist Therapeutics Inc. from a major institutional investor.
• The filing confirms a significant institutional holding, which can provide stability and liquidity to the stock.

Negatives

• The filing does not contain any negative financial results or operational challenges for Protagonist Therapeutics Inc. itself, as it is a disclosure of ownership by an external entity.

Risks

• Potential for future changes in State Street Corporation's holdings, which could impact Protagonist Therapeutics Inc.'s stock price.
• The filing does not detail the specific investment strategy or rationale behind State Street's position, leaving the long-term intent unclear.

Future Outlook

The filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance from Protagonist Therapeutics Inc.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are standard disclosures for institutional investors crossing certain ownership thresholds. State Street Corporation, through its various asset management arms like SSGA, is a significant global investor, and its holdings in biotechnology companies like Protagonist Therapeutics Inc. reflect ongoing institutional interest in the sector.

Stakeholder Impact

• Shareholders: The filing confirms a significant institutional investor's stake, which may be viewed positively for stock stability, but also implies potential for future trading activity by State Street.
• Management of Protagonist Therapeutics Inc.: The presence of a large institutional holder like State Street can influence corporate governance discussions and strategic decisions.
• Potential Investors: The filing provides transparency on ownership structure, aiding in investment analysis.

Next Steps

• Protagonist Therapeutics Inc. may see continued interest from institutional investors.
• State Street Corporation may adjust its holdings in Protagonist Therapeutics Inc. in the future, which would be reported in subsequent filings.

Key Dates

Keywords

Schedule 13G, State Street Corporation, Protagonist Therapeutics Inc., Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, CUSIP, SSGA